Company intelligence / Profile preview

TSB Therapeutics

Beijing, China

Ownership: Private
Development stage: Other

Overview

Amubarvimab/romlusevimab combination therapy approved by China's NMPA on 08 Dec 2021 for mild/normal COVID-19 in adults and pediatrics aged 12-17 at high risk; commercially launched in China

Therapeutic areas: Infectious Diseases
Modalities: Monoclonal antibody
Industry: Biotech

Partnerships

CR Pharma (commercialization in China)Sinopharm (commercialization in China)Tsinghua University (development)3rd People’s Hospital of Shenzhen (development and establishment)

Beyond the preview

Go deeper on TSB Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TSB Therapeutics.

Explore the full profile